Levetiracetam Medical Valley (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and decreases abnormal neuronal excitability, thereby limiting the spread of epileptic activity in the brain.

The appropriate dose of levetiracetam is determined by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many traditional antiepileptics such as carbamazepine or phenytoin. It is often chosen for its broad spectrum of activity across seizure types and its ease of dosing, though individual response varies.

Levetiracetam Medical Valley should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Levetiracetam is taken orally, usually as a tablet, with or without food. The exact administration schedule—once or twice daily—depends on the prescriber’s recommendation and the patient’s therapeutic needs.

Serious risks include severe allergic reactions, mood alterations such as depression or suicidal thoughts, and rare skin conditions like Stevens‑Johnson syndrome. Patients should be monitored closely for any new or worsening symptoms and seek medical attention promptly.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its components. Caution is advised for patients with severe renal impairment, and it should be avoided in those for whom the risk‑benefit profile is unfavorable.